TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03950596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Questionnaire
Description: Pain questionnaire regarding pain in the knee during previous 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Questionnaire
Description: Pain questionnaire regarding pain in the knee during previous 3 months

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA and RNA test
Description: DNA and RNA tests will be sent to a genetic laboratory for analysis

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA and RNA test
Description: DNA and RNA tests will be sent to a genetic laboratory for analysis
Study: NCT01000623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypnotherapy
Description: Practice hypnosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypnotherapy
Description: Practice hypnosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mind-body intervention procedure
Description: Practice focused attention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mind-body intervention procedure
Description: Practice focused attention
Study: NCT01242748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin acetate
Description: The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
Study: NCT01827826

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic intervention to prevent Diabetes Mellitus, Type 2
Description: Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
Study: NCT00803790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium+vitamin D combination
Description: A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: alendronate
Description: A single dose tablet of 70mg alendronate in one treatment period of each sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: alendronate
Description: A single dose tablet of 70mg alendronate in one treatment period of each sequence.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparator: Vitamin D
Description: Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparator: Vitamin D
Description: Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
Study: NCT03231202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist.
Study: NCT01932710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White Blood Cell Transfusion
Description: Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
Study: NCT02789683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fine emulsion
Description: Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coarse emulsion
Description: Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
Study: NCT04357288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
Study: NCT02787824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose Supplement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose Supplement
Study: NCT01725581

Intervention type: PROCEDURE
Intervention: Observed Structured Assessment Tool in Pelvic Examination
Description: Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
Study: NCT04357288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encounter Decision Aid
Description: The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encounter Decision Aid
Description: The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
Study: NCT01900600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary exercise test
Description: All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary exercise test
Description: All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary exercise test
Description: All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cardiopulmonary exercise test
Description: All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
Study: NCT04206319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: an alpha particle-emitting drug, dose consists of 55 kBq/kg (1.49 microcurie/kg); administered every 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F Sodium Fluoride
Description: 18F-NaF (Sodium Fluoride) is a radio-pharmaceutical used to image skeletal pathology with positron emission tomography (PET) imaging
Study: NCT03025789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
Study: NCT00699439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based asthma flow diagram
Description: If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
Study: NCT00514943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: experimental drug taken once daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: active comparator administered weekly intravenously
Study: NCT03559088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine App
Description: Smart phone app used to report migraine burden to the EHR.
Study: NCT01875354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplements and TR90 Eating Plan
Description: Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Low Fat Eating Plan
Study: NCT02965963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Study: NCT03950596

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA and RNA test
Description: DNA and RNA tests will be sent to a genetic laboratory for analysis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound of the knee joint and the quadriceps muscle and the pica tendon

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound of the knee joint and the quadriceps muscle and the pica tendon

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound of the knee joint and the quadriceps muscle and the pica tendon

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Needle Core Biopsy
Description: Core Biopsy will be taken from the quadriceps femoris muscle
Study: NCT03876574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intra-arterially for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Given intra-arterially continuously for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given intra-arterially continuously with 5-FUDR
Study: NCT05468164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally
Study: NCT02965963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Study: NCT05468164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally
Study: NCT01725581

Intervention type: PROCEDURE
Intervention: Observed Structured Assessment Tool in Pelvic Examination
Description: Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.

Intervention type: PROCEDURE
Intervention: Observed Structured Assessment Tool in Pelvic Examination
Description: Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
Study: NCT00792974

Intervention type: BEHAVIORAL
Intervention: A brief psycho-educational intervention
Description: A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.~This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment.
Study: NCT02965963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Study: NCT02362477

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy in-person
Description: Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy through videoteleconference
Description: Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
Study: NCT03866850

Intervention type: BEHAVIORAL
Intervention: Phase duration
Description: We will vary the phase duration in the stimulation, and examine detection threshold, spatial spread of neural excitation, and speech recognition as the outcomes.
Study: NCT02965963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - 60%
Description: 60% of VO2max
Study: NCT04928651

Intervention type: DRUG
Intervention: Clonidine
Description: Clonidine will be administered to preterm infants in need of analgesia and sedation; either as the primary drug for comfort and light sedation or as an add-on drug to opioids according to an algorithm based on pain and sedative scoring results. Opioids are mostly given to postoperative patients. These drugs (morphine or fentanyl) will not be studied, but a baseline PK sample will be taken to correlate to the baseline aEEG.
Study: NCT02907112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meat reduction
Description: Advice, Motivational material and food products provided to participants
Study: NCT01877707

Intervention type: OTHER
Group type: OTHER
Intervention: home monitoring
Description: Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
Study: NCT02545998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telehealthcare
Description: Telephone consultation plus e-mail with attached PAAP and video link
Study: NCT03029520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation with iRoot SP sealer
Description: Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation with iRoot SP sealer
Description: Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation with AH Plus Sealer
Description: Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation with AH Plus Sealer
Description: Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
Study: NCT01924871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane with remifentanil
Description: During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
Study: NCT00492089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT02965963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - 60%
Description: 60% of VO2max

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - 60%
Description: 60% of VO2max

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - 85%
Description: 85% of VO2max

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - 85%
Description: 85% of VO2max

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - 85%
Description: 85% of VO2max
Study: NCT00492089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: magnetic resonance imaging
Study: NCT03406819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroprusside Sodium
Description: Intracoronary infusion 50\~100μg each time (repeated)
Study: NCT00492089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT03406819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Hydrochloride
Description: Intracoronary infusion 10μg/kg for single time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparinized saline
Description: Intracoronary infusion 2ml for single time
Study: NCT00492089

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT02486796

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reishi mushroom extract
Description: Reishi mushroom preparation produced water-ethanol extraction.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reishi mushroom extract
Description: Reishi mushroom preparation produced water-ethanol extraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Preparation of coenzyme Q10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Preparation of coenzyme Q10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Preparation of melatonin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Preparation of melatonin
Study: NCT02687009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.